Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer’s Disease: Results from the DIAN Study Group
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
Amyloid imaging plays an important role in the research and diagnosis of dementing disorders. Substantial variation in quantitative methods to measure brain amyloid burden exists in the field. The aim of this work is to investigate the impact of methodological variations to the quantification of amyloid burden using data from the Dominantly Inherited Alzheimer's Network (DIAN), an autosomal dominant Alzheimer's disease population. Cross-sectional and longitudinal [11C]-Pittsburgh Compound B (PiB) PET imaging data from the DIAN study were analyzed. Four candidate reference regions were investigated for estimation of brain amyloid burden. A regional spread function based technique was also investigated for the correction of partial volume effects. Cerebellar cortex, brain-stem, and white matter regions all had stable tracer retention during the course of disease. Partial volume correction consistently improves sensitivity to group differences and longitudinal changes over time. White matter referencing improved statistical power in the detecting longitudinal changes in relative tracer retention; however, the reason for this improvement is unclear and requires further investigation. Full dynamic acquisition and kinetic modeling improved statistical power although it may add cost and time. Several technical variations to amyloid burden quantification were examined in this study. Partial volume correction emerged as the strategy that most consistently improved statistical power for the detection of both longitudinal changes and across-group differences. For the autosomal dominant Alzheimer's disease population with PiB imaging, utilizing brainstem as a reference region with partial volume correction may be optimal for current interventional trials. Further investigation of technical issues in quantitative amyloid imaging in different study populations using different amyloid imaging tracers is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Su et al. 42,49 has demonstrated that the RSF technique was able to improve PET quantification and achieve better sensitivity to longitudinal changes in amyloid burden.”
From OASIS-3: Longitudinal Neuroimaging, Clinical, and Cognitive Dataset for Normal Aging and Alzheimer Disease (2019) · cites this paper as [49]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882 · cited 2×
“In comparison, in this current study in the DIAN cohort using PiB as the tracer, we observed a substantially larger annual rate of 0.02±0.03 in SUVR in a cohort that is a mixture of MCI (CDR = 0.5) and asymptomatic participants using similar reference region.”
MethodInfluentialSelf-citation2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · cited 1×
“The DIAN includes individuals from families with known autosomal dominant mutation in amyloid precursor protein [27], presenilin 1 [28], or presenilin 2 [29] genes leading to early onset AD.”
BackgroundCloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051 · cited 1×
“The DIAN includes individuals from families with known autosomal dominant mutation in amyloid precursor protein [27], presenilin 1 [28], or presenilin 2 [29] genes leading to early onset AD.”
BackgroundHearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Self-citationCandidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577 · cited 1×
“The DIAN includes individuals from families with known autosomal dominant mutation in amyloid precursor protein [27], presenilin 1 [28], or presenilin 2 [29] genes leading to early onset AD.”
BackgroundSimplified Reference Tissue Model for PET Receptor Studies
Lammertsma, A. A., & Hume, S. P. (1996) · NeuroImage · doi:10.1006/nimg.1996.0066 · Cited by 2,021 · cited 1×
“Alternatively, kinetic modeling techniques [23,24] can be used to calculate distribution volume ratio (DVR) or binding potential (BPND) as a quantitative measure of amyloid burden [11,22].”
MethodPartial-Volume Effect in PET Tumor Imaging
Soret, M., Bacharach, S. L., & Buvat, I. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.035774 · Cited by 1,549 · cited 1×
“PET imaging based measurement is subjected to partial volume effects, because of the low spatial resolution [19].”
BackgroundDistribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data
Logan, J., Fowler, J. S., Volkow, N. D., Wang, G.-J., Ding, Y.-S., & Alexoff, D. L. (1996) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199609000-00008 · Cited by 1,514 · cited 2×
“Alternatively, kinetic modeling techniques [23,24] can be used to calculate distribution volume ratio (DVR) or binding potential (BPND) as a quantitative measure of amyloid burden [11,22].”
Method
Cited by
LaMontagne, P. J., Benzinger, T. L., Morris, J. C., Keefe, S., Hornbeck, R., Xiong, C., Grant, E., Hassenstab, J., Moulder, K., Vlassenko, A. G., et al. (2019) · medRxiv · doi:10.1101/2019.12.13.19014902 · Cited by 779
“Su et al. 42,49 has demonstrated that the RSF technique was able to improve PET quantification and achieve better sensitivity to longitudinal changes in amyloid burden.”
Self-citationLa Joie, R., Ayakta, N., Seeley, W. W., Borys, E., Boxer, A. L., DeCarli, C., Doré, V., Grinberg, L. T., Huang, E., Hwang, J., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.09.001 · Cited by 317
Self-citationLongitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease
McDade, E., Wang, G., Gordon, B. A., Hassenstab, J., Benzinger, T. L. S., Buckles, V., Fagan, A. M., Holtzman, D. M., Cairns, N. J., Goate, A. M., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000006277 · Cited by 314
“We have previously demonstrated that for PiB-PET there were no significant differences in results when using a cerebellar, pons, or white matter reference.(21)”
ResultSelf-citationGonzalez-Escamilla, G., Lange, C., Teipel, S., Buchert, R., & Grothe, M. J. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2016.12.077 · Cited by 186
Standardized Expression of 18F-NAV4694 and 11C-PiB β-Amyloid PET Results with the Centiloid Scale
Rowe, C. C., Jones, G., Doré, V., Pejoska, S., Margison, L., Mulligan, R. S., Chan, J. G., Young, K., & Villemagne, V. L. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.171595 · Cited by 140
Self-citationUtilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies
Su, Y., Flores, S., Hornbeck, R. C., Speidel, B., Vlassenko, A. G., Gordon, B. A., Koeppe, R. A., Klunk, W. E., Xiong, C., Morris, J. C., et al. (2018) · NeuroImage: Clinical · doi:10.1016/j.nicl.2018.04.022 · Cited by 126
Self-citationEtiology of White Matter Hyperintensities in Autosomal Dominant and Sporadic Alzheimer Disease
Shirzadi, Z., Schultz, S. A., Yau, W. W., Joseph‐Mathurin, N., Fitzpatrick, C. D., Levin, R., Kantarci, K., Preboske, G. M., Jack, C. R., Farlow, M. R., et al. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2023.3618 · Cited by 95
Self-citationSocioeconomic Status Mediates Racial Differences Seen Using the AT(N)Framework
Meeker, K. L., Wisch, J. K., Hudson, D., Coble, D., Xiong, C., Babulal, G. M., Gordon, B. A., Schindler, S. E., Cruchaga, C., Flores, S., et al. (2021) · Annals of Neurology · doi:10.1002/ana.25948 · Cited by 68
“PET amyloid imaging was performed with either [(11)C] Pittsburgh Compound B (PiB) or [(18)F]-Flobetapir (AV45).(35,36) The time window for quantification was 30 to 60 minutes postinjection for PiB and 50 to 70 minutes for AV45.”
MethodSelf-citationThe relevance of cerebrospinal fluid α-synuclein levels to sporadic and familial Alzheimer’s disease
for the Dominantly Inherited Alzheimer Network (DIAN), Twohig, D., Rodriguez-Vieitez, E., Sando, S. B., Berge, G., Lauridsen, C., Møller, I., Grøntvedt, G. R., Bråthen, G., Patra, K., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0624-z · Cited by 68
Self-citationWidespread distribution of tauopathy in preclinical Alzheimer's disease
Schultz, S. A., Gordon, B. A., Mishra, S., Su, Y., Perrin, R. J., Cairns, N. J., Morris, J. C., Ances, B. M., & Benzinger, T. L. S. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.08.022 · Cited by 64
Self-citationMallik, A. K., Drzezga, A. E., & Minoshima, S. (2016) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.005 · Cited by 69
“Although there is no need to predict impending clinical AD dementia in this patient group, selecting these patients provides important information about the distribution and time course of Aβ deposition in relation to disease progression.(145) Interestingly, ADAD patients with APP or PSEN1mutation demonstrate more dif…”
BackgroundAlzheimer's disease and blood-based biomarkers – potential contexts of use
Zvěřová, M. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s172285 · Cited by 51
Discovery and validation of autosomal dominant Alzheimer’s disease mutations
Dominantly Inherited Alzheimer Network (DIAN), Hsu, S., Gordon, B. A., Hornbeck, R. C., Norton, J. B., Levitch, D., Louden, A., Ziegemeier, E., Laforce, R. J., Chhatwal, J. P., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0392-9 · Cited by 50
Self-citationMcKay, N. S., Gordon, B. A., Hornbeck, R. C., Dincer, A., Flores, S. E., Keefe, S., Joseph‐Mathurin, N., Jack, C. R., Koeppe, R. A., Millar, P. R., et al. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01359-8 · Cited by 53
“6.”
Self-citationLongitudinal validity of PET‐based staging of regional amyloid deposition
Jelistratova, I., Teipel, S. J., & Grothe, M. J. (2020) · Human Brain Mapping · doi:10.1002/hbm.25121 · Cited by 39
“…images, which has previously been shown to improve amyloid-PET quantification (Brendel et al., 2015; Gonzalez-Escamilla et al., 2017; Rullmann et al., 2016; Su et al., 2016), particularly by accounting for confounding effects of high nonspecific white matter binding (Matsubara et al., 2016).”
BackgroundFleisher, A., Joshi, A. D., Sundell, K. L., Chen, Y., Kollack‐Walker, S., Lu, M., Chen, S., Devous, M. D., Seibyl, J. P., MAREK, K. L., et al. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.02.009 · Cited by 41
“used four candidate reference regions (cerebellar cortex, brainstem, and both [core and total] white matter regions) to estimate brain amyloid burden with data from the Dominantly Inherited Alzheimer’s Network, an autosomal dominant AD population [29].”
Method[11C]PIB amyloid quantification: effect of reference region selection
Heeman, F., Hendriks, J., Alves, I. L., Ossenkoppele, R., Tolboom, N., van Berckel, B. N. M., Lammertsma, A. A., & Yaqub, M. M. (2020) · EJNMMI Research · doi:10.1186/s13550-020-00714-1 · Cited by 40
“It should be noted, however, that these results belong to a group classification analysis, and hence they cannot be compared directly with findings from studies assessing the statistical power for detecting longitudinal changes in Aβ burden, that employ a within-subject design [32, 34].”
MethodResultWisch, J. K., McKay, N. S., Boerwinkle, A. H., Kennedy, J., Flores, S., Handen, B. L., Christian, B. T., Head, E., Mapstone, M., Rafii, M. S., et al. (2024) · The Lancet Neurology · doi:10.1016/s1474-4422(24)00084-x · Cited by 37
Self-citationOrtner, M., Drost, R., Hedderich, D. M., Goldhardt, O., Müller‐Sarnowski, F., Diehl‐Schmid, J., Förstl, H., Yakushev, I. Y., & Grimmer, T. (2019) · BMC Neurology · doi:10.1186/s12883-019-1498-9 · Cited by 32
Vascular endothelial‐cadherin as a marker of endothelial injury in preclinical Alzheimer disease
Tarawneh, R. M., Kasper, R. S., Sanford, J., Phuah, C., Hassenstab, J. J., & Cruchaga, C. (2022) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51685 · Cited by 29
Autosomal dominantly inherited alzheimer disease: Analysis of genetic subgroups by machine learning
Castillo-Barnés, D., Su, L., Ramírez, J., Salas-Gonzalez, D., Martínez-Murcia, F. J., Illán, I. A., Segovia, F., Ortíz, A., Cruchaga, C., Farlow, M. R., et al. (2020) · Information Fusion · doi:10.1016/j.inffus.2020.01.001 · Cited by 32
“Findings obtained from DIAD can be extrapolated to the sporadic LOAD so it is expected that better treatments will be prescribed at pre-clinical stages of the disease when damage is minimal and pathogenesis can be slowed down or even prevented from progressing [7, 29, 30, 31, 24, 5].”
BackgroundSelf-citationGhisays, V., Lopera, F. J., Goradia, D. D., Protas, H. D., Malek‐Ahmadi, M. H., Chen, Y., Devadas, V., Luo, J., Lee, W., Baena, A. Y., et al. (2021) · NeuroImage Clinical · doi:10.1016/j.nicl.2021.102749 · Cited by 31
“…and quantitative Aβ PET measurements using pons as the reference region (i.e., cerebellar SUVR_pons and distribution volume ratios [DVR] (Su et al., 2016) were used to provide evidence of cerebellar Aβ plaque deposition and its relationships with age, cortical measures of Aβ (i.e.,…”
MethodSelf-citationAssociation between personality and tau-PET binding in cognitively normal older adults
Schultz, S. A., Gordon, B. A., Mishra, S., Su, Y., Morris, J. C., Ances, B. M., Duchek, J. M., Balota, D. A., & Benzinger, T. L. S. (2019) · Brain Imaging and Behavior · doi:10.1007/s11682-019-00163-y · Cited by 28
“1b) (Su et al. 2016; Su et al. 2013).”
Self-citationHead-to-Head Comparison of 18F-Florbetaben and 18F-Flutemetamol in the Cortical and Striatal Regions
Cho, S. H., Choe, Y. S., Kim, Y. J., Kim, H. J., Jang, H., Kim, Y., Kim, S. E., Kim, S. J., Kim, J. P., Jung, Y. H., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200079 · Cited by 25
“It is difficult to compare and interpret results from research performed with different ligands and imaging techniques because the calculated SUVRs of studies differ [13].”
A new integrated dual time-point amyloid PET/MRI data analysis method
Cecchin, D., Barthel, H., Poggiali, D., Cagnin, A., Tiepolt, S., Zucchetta, P., Turco, P., Gallo, P., Frigo, A. C., Sabri, O., et al. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3750-0 · Cited by 25
“Furthermore, in view of the fact that PVEC has been proved as a strategy that improves the statistical power to detect longitudinal changes and across-group differences [51], we included MR-based PVEC with parcellation in our method as part of the dual time-window process.”
MethodFuture Directions in Imaging Neurodegeneration
Masdeu, J. C. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0718-1 · Cited by 23
18F-FIBT may expand PET for β-amyloid imaging in neurodegenerative diseases
Grimmer, T., Shi, K., Diehl‐Schmid, J., Natale, B., Drzezga, A. E., Förster, S., Förstl, H., Schwaiger, M., Yakushev, I. Y., Wester, H., et al. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0203-5 · Cited by 20
Self-citationNeuroimaging of Diseases Causing Dementia
Masdeu, J. C. (2019) · Neurologic Clinics · doi:10.1016/j.ncl.2019.08.003 · Cited by 16
Initiative, A. D. N., González‐Escamilla, G., Miederer, I., Grothe, M. J., Schreckenberger, M., Muthuraman, M., & Groppa, S. (2020) · Brain Imaging and Behavior · doi:10.1007/s11682-019-00247-9 · Cited by 17
Association of Tau Pathology With Clinical Symptoms in the Subfields of Hippocampal Formation
Ge, X., Zhang, D., Qiao, Y., Zhang, J., Xu, J., & Zheng, Y. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.672077 · Cited by 17
Differentiating amyloid beta spread in autosomal dominant and sporadic Alzheimer’s disease
Levitis, E., Vogel, J. W., Funck, T., Hachinski, V., Gauthier, S. G., Vöglein, J., Levin, J., Gordon, B. A., Benzinger, T. L. S., Iturria‐Medina, Y., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcac085 · Cited by 18
Self-citationProteomic clusters underlie heterogeneity in preclinical Alzheimer’s disease progression
Wisch, J. K., Butt, O. H., Gordon, B. A., Schindler, S. E., Fagan, A. M., Henson, R. L., Yang, C., Boerwinkle, A. H., Benzinger, T. L. S., Holtzman, D. M., et al. (2023) · Brain · doi:10.1093/brain/awac484 · Cited by 11
Self-citation15 years of longitudinal genetic, clinical, cognitive, imaging, and biochemical measures in DIAN
Daniels, A. J., McDade, E., Llibre‐Guerra, J. J., Xiong, C., Perrin, R. J., Ibáñez, L., Supnet‐Bell, C., Cruchaga, C., Goate, A., Renton, A. E., et al. (2026) · npj Dementia · doi:10.1038/s44400-025-00047-7 · Cited by 12
Self-citationMolecular neuroimaging in dominantly inherited versus sporadic early-onset Alzheimer’s disease
Iaccarino, L., Llibre‐Guerra, J. J., McDade, E., Edwards, L., Gordon, B. A., Benzinger, T. L. S., Hassenstab, J. J., Kramer, J. H., Li, Y., Miller, B. L., et al. (2024) · Brain Communications · doi:10.1093/braincomms/fcae159 · Cited by 11
“Given that this choice could have biased the PIB-PET comparisons, we repeated the global binding analyses after excluding N = 2 amyloid-positive CN and N = 9 amyloid-negative DIAD participants, as defined by the A ± status provided by the DIAN PET Core (approach described in Su et al .”
MethodSelf-citationKameyama, M., Ishibash, K., Wagatsuma, K., Toyohara, J., & Ishii, K. (2019) · Annals of Nuclear Medicine · doi:10.1007/s12149-019-01397-y · Cited by 11
Schultz, S. A., Shirzadi, Z., Schultz, A. P., Liu, L., Fitzpatrick, C. D., McDade, E., Barthélemy, N. R., Renton, A. E., Esposito, B. T., Joseph‐Mathurin, N., et al. (2023) · Aging Cell · doi:10.1111/acel.13871 · Cited by 10
“A composite SUVR for mean cortical A β deposition measure was gener - ated using the average across the left and right lateral orbitofrontal, medial orbitofrontal, rostral middle frontal, superior frontal, superior temporal, middle temporal, and precuneus regions (Su et al., 2013, 2016 ).”
Self-citationSu, Y., Blazey, T., Owen, C. J., Christensen, J. J., Friedrichsen, K. A., Joseph‐Mathurin, N., Wáng, Q., Hornbeck, R. C., Ances, B. M., Snyder, A. Z., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163669 · Cited by 10
Self-citationEnhancing Amyloid PET Quantification: MRI-Guided Super-Resolution Using Latent Diffusion Models
Shah, J., Che, Y., Sohankar, J., Luo, J., Li, B., Su, Y., Wu, T., & Initiative, A. D. N. (2024) · Life · doi:10.3390/life14121580 · Cited by 11
“We also test whether the LDM-RR corrected FBP MCSUVR is more strongly associated with PIB MCSUVR than the RL method.”
Self-citationAssessment of Instrumental Activities of Daily Living in Preclinical Alzheimer Disease
Keleman, A. A., Bollinger, R. M., Wisch, J. K., Grant, E., Benzinger, T. L. S., Ances, B. M., & Stark, S. L. (2022) · OTJR Occupational Therapy Journal of Research · doi:10.1177/15394492221100701 · Cited by 11
“Centiloids were used to coordinate measures from tracers PiB and AV45 (Mishra et al., 2017; Su et al., 2016).”
MethodSelf-citationRegional patterns of 18F-florbetaben uptake in presenilin 1 mutation carriers
Sala‐Llonch, R., Falgàs, N., Bosch, B., Fernández‐Villullas, G., Balasa, M., Antonell, A., Perissinotti, A., Pavía, J., Campos, F., Lladó, A., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.04.010 · Cited by 8
Precipitating Mechanisms of Falls in Preclinical Alzheimer’s Disease
Keleman, A. A., Nicosia, J., Bollinger, R. M., Wisch, J. K., Hassenstab, J. J., Morris, J. C., Ances, B. M., Balota, D. A., & Stark, S. L. (2023) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-230002 · Cited by 10
“All data were converted to standardized uptake value ratios with the cerebellar cortex used as a reference region before then being converted to the Centiloid scale [23, 24].”
MethodSelf-citationNeuroimaging within the Dominantly Inherited Alzheimer’s Network (DIAN): PET and MRIPreprint
McKay, N. S., Gordon, B. A., Hornbeck, R. C., Jack, C. R., Koeppe, R. A., Flores, S. E., Keefe, S., Hobbs, D. A., Joseph‐Mathurin, N., Wang, Q., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.25.485799 · Cited by 10
Self-citationModeling neurodegenerative disorders in adult somatic cells: A critical review
Truong, A. N., Si, E., Duncan, T., & Valenzuela, M. (2016) · Frontiers in Biology · doi:10.1007/s11515-016-1413-3 · Cited by 7
“Given the abundance of research in FAD (e.g., DIAN project (Cairns et al., 2015; Su et al., 2016), in the near future it may be interesting to apply gene editing technology on patient-specific iNs or iPSC-derived neurons to examine whether rescue of point mutations can ameliorate disease phenotype…”
BackgroundEarly syndecan-4 upregulation predicts cognitive and pathological trajectories in Alzheimer disease
Tarawneh, R. M., Moulder, K. L., Topouza, D. G., Kar, A., Qian, H., Pankratz, V. S., Timsina, J., Franklin, E. E., Schindler, S. E., Perrin, R. J., et al. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-026-02043-2 · Cited by 5
“…imaging using the amyloid ligand Pittsburgh Compound-B (PiB; n = 528) or 18 F-AV-45 (Avid Radiopharmaceuticals, n = 191) was obtained in a subset of participants ( n = 719) using the standard protocol (30–60 min postinjection as the time window for PiB and 50–70 min for 18 F-AV-45) [35–37].”
Self-citationA kinetics-based approach to amyloid PET semi-quantification
Chincarini, A., Peira, E., Corosu, M., Morbelli, S. D., Bauckneht, M., Capitanio, S., Pardini, M., Arnaldi, D., Vellani, C., D’Ambrosio, D., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04689-y · Cited by 6
Schultz, S. A., Liu, L., Schultz, A. P., Fitzpatrick, C. D., Levin, R., Bellier, J., Shirzadi, Z., Joseph‐Mathurin, N., Chen, C. D., Benzinger, T. L. S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.07.04.547688 · Cited by 6
Self-citationSchultz, S. A., Rao, Y., Liu, L., Ostaszewski, B. L., Anderson, A. K., Yau, W. W., Shirzadi, Z., Gordon, B. A., Hassenstab, J. J., Morris, J. C., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71049 · Cited by 1
“30,31 2.”
Self-citationMcDade, E., Porsteinsson, A., Clifford, D. B., Llibre‐Guerra, J. J., Wang, G., Li, Y., Belyew, S., Mills, S., Santacruz, A., Supnet‐Bell, C., et al. (2026) · npj Dementia · doi:10.1038/s44400-026-00067-x · Cited by 1
Self-citationMolecular Imaging and Precision Medicine in Dementia and Movement Disorders
Mallik, A. K., Drzezga, A. E., & Minoshima, S. (2016) · PET Clinics · doi:10.1016/j.cpet.2016.08.003 · Cited by 1
Proteomic Clusters Underlie Heterogeneity in Preclinical AD ProgressionPreprint
Wisch, J. K., Butt, O. H., Gordon, B. A., Schindler, S. E., Fagan, A. M., Yang, C., Boerwinkle, A. H., Benzinger, T. L. S., Holtzman, D. M., Morris, J. C., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1257861/v1 · Cited by 1
Self-citationMistlberger, R. E., & Kent, B. A. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734019088.793552993 · Cited by 1
Technical Considerations on Scanning and Image Analysis for Amyloid PET in Dementia
Akamatsu, G., Ohnishi, A., Aita, K., Ikari, Y., Yamamoto, Y., & Senda, M. (2017) · Japanese Journal of Radiological Technology · doi:10.6009/jjrt.2017_jsrt_73.4.298 · Cited by 2
Image-based biomedical data modeling and parametric imaging
Wen, L., Eberl, S., FULHAM, M. J., & Feng, D. D. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816034-3.00015-8
Understanding emerging biomarkers and lifestyle factors in aging and Alzheimer disease
Schultz, S. A. (2020) · Open Scholarship Institutional Repository (Washington University in St. Louis) · doi:10.7936/2y01-5674
Proteomic Clusters Underlie Heterogeneity in Preclinical AD ProgressionPreprint
Wisch, J. K., Butt, O. H., Gordon, B. A., Schindler, S. E., Fagan, A. M., Yang, C., Boerwinkle, A. H., Benzinger, T. L. S., Holtzman, D. M., Morris, J. C., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1257861/v2
Self-citationA Novel Dual Time-Point Unified Amyloid MRI/PET Data Analysis Technique
Vekariya, V., & Kumari, A. (2023) · International Conference on Artificial Intelligence and Smart Communication (AISC) · doi:10.1109/aisc56616.2023.10084979
Accounting for white matter uptake improves between tracer agreement in amyloid PET
Chen, Y., Protas, H. D., Luo, J., Li, S., Sohankar, J., Pan, C., Ghisays, V., Lee, W., Wu, T., Chen, D., et al. (2025) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.70165
Self-citationMeasuring White Matter Changes in Alzheimer’s Disease Using a Novel Technique
Bhargava, V., & Bhargava, V. (2024) · UA Campus Repository (The University of Arizona)
Metadata
- Authors
- Su, Y., Blazey, T. M., Owen, C. J., Christensen, J. J., Friedrichsen, K., Joseph-Mathurin, N., Wang, Q., Hornbeck, R. C., Ances, B. M., Snyder, A. Z., Cash, L. A., Koeppe, R. A., Klunk, W. E., Galasko, D., Brickman, A. M., McDade, E., Ringman, J. M., Thompson, P. M., Saykin, A. J., Ghetti, B., Sperling, R. A., Johnson, K. A., Salloway, S. P., Schofield, P. R., Masters, C. L., Villemagne, V. L., Fox, N. C., Förster, S., Chen, K., Reiman, E. M., Xiong, C., Marcus, D. S., Weiner, M. W., Morris, J. C., Bateman, R. J., Benzinger, T. L. S., & Dominantly Inherited Alzheimer Network
- Affiliations
- Washington University in St. Louis (US)
- University of Michigan (US)
- University of Pittsburgh (US)
- University of California San Diego (US)
- Columbia University (US)
- University of Southern California (US)
- Indiana University Indianapolis (US)
- Harvard University (US)
- Brown University (US)
- UNSW Sydney (AU)
- The University of Melbourne (AU)
- UCL Queen Square Institute of Neurology (GB)
- German Center for Neurodegenerative Diseases (DE)
- Banner Health (US)
- University of California, San Francisco (US)
- Corresponding author
- Su, Yi
- ORCID
- Su, Yi
- Blazey, Tyler M.
- Friedrichsen, Karl
- Wang, Qing
- Hornbeck, Russ C.
- Ances, Beau M.
- Snyder, Abraham Z.
- Koeppe, Robert A.
- Klunk, William E.
- Brickman, Adam M.
- McDade, Eric
- Ringman, John M.
- Thompson, Paul M.
- Saykin, Andrew J.
- Ghetti, Bernardino
- Sperling, Reisa A.
- Johnson, Keith A.
- Salloway, Stephen P.
- Schofield, Peter R.
- Masters, Colin L.
- Villemagne, Victor L.
- Fox, Nick C.
- Förster, Stefan
- Chen, Kewei
- Reiman, Eric M.
- Xiong, Chengjie
- Marcus, Daniel S.
- Weiner, Michael W.
- Morris, John C.
- Bateman, Randall J.
- Benzinger, Tammie L. S.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-03-24
- Volume
- 11
- Issue
- 3
- Pages
- e0152082
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4807073
- OpenAlex
- W2316313792
- Semantic Scholar
- 17effc405abab01da955a23a9c372449e994197a
- Cited by
- 56
- References
- 45
- Citations by year
- 2026: 4 · 2025: 1 · 2024: 3 · 2023: 6 · 2022: 7 · 2021: 2 · 2020: 7 · 2019: 7 · 2018: 9 · 2017: 4 · 2016: 6
- FWCI
- 7.70
- Type
- journal article
- Language
- en
- Update notices
- correction (2016-09-20)
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- D-Scholarship@Pitt (University of Pittsburgh) (acceptedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- UNSWorks (UNSW Sydney) (submittedVersion, cc-by-nc-nd)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- DZNE Pub (submittedVersion, cc-by)
- Columbia Academic Commons (Columbia University)
- Funders
- Alzheimer's Disease Neuroimaging Initiative (P01AG026276)
- Institute of Clinical and Translational Sciences (UL1TR000448)
- Georgia Clinical and Translational Science Alliance (UL1TR000448)
- National Institute for Health and Care Research (NF-SI-0513-10134)
- National Institutes of Health (UL1TR000448)
- Charles F. and Joanne Knight Alzheimer Disease Research Center, Washington University in St. Louis (U19AG032438, P50AG005681, P30NS048056, P01AG003991, P01AG026276)
- National Institute on Aging (P30AG053760, P50AG005131, UF1AG032438, P50AG005681, P50AG005142, P01AG003991, U19AG032438, P01AG026276)
- National Institute of Neurological Disorders and Stroke (P01NS080675, P30NS048056)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- amyloid imaging, autosomal dominant Alzheimer's disease, 11C-Pittsburgh compound B, PiB PET, partial volume correction, reference region, spread function, kinetic modeling
- MeSH terms
- Adult, Alzheimer Disease, Amyloid, Brain, Carbon Isotopes, Cross-Sectional Studies, DNA Mutational Analysis, Family Health, Female, Genes, Dominant, Heterozygote, Humans, Image Processing, Computer-Assisted, Longitudinal Studies, Male, Middle Aged, Mutation, Reference Values, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
